TC
Timefolio Capital (formerly known as NS Investment) is a Seoul-based venture capital firm affiliated with Dong-A ST (and later Timefolio Asset Management) that invests in novel therapeutic and biotech companies, primarily in the US and Korea. It was established in 2015 as the biotech venture capital arm of Dong-A ST.
50% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $99.9M (across 4 rounds with reported amounts).
Portfolio
10
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
KL
KyungEun LEE
투자 팀장
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Accent Therapeutics | Series C | $75M | Jan 2024 |
 Mezoo | Unknown | — | Nov 2023 |
 BoostImmune | Series A | — | Jun 2022 |
 Aspen Neuroscience | Series B | $147.5M | May 2022 |
 Dewpoint Therapeutics | Series C | $150M | Feb 2022 |
 Inventage Lab | Unknown | — | — |
 StradVision | Series B | $27M | — |
 Enhans | Series A | — | — |
 Medimabbio | Series B | — | — |
| AAdel | Ipo | — | — |
Top Co-Investors
Mirae Asset3 shared
AJU IB Investment3 shared
Smilegate Investment3 shared
ARCH Venture Partners2 shared
GV2 shared
Woori Venture Partners2 shared
Industrial Bank of Korea2 shared
Mirae Asset Securities2 shared
BECO Capital1 shared
Leaps by Bayer1 shared
Maverick Ventures1 shared
3E Bioventures Capital1 shared
General Catalyst1 shared
Mubadala Ventures1 shared
Samsara BioCapital1 shared
Polaris Partners1 shared
SoftBank Vision Fund1 shared
Primary Venture Partners1 shared
Lifeforce Capital1 shared
EDBI1 shared
Last updated: 8 September 2026